The August 1, 2019, article by Ma et al entitled “Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma” (J Clin Oncol 10.1200/JCO.19.00463) was published with an error.
The first full sentence in the left column on page 1913 was given as:
In the definitive setting, phase III efforts include NRG HN002, which has randomly assigned patients to 60 Gy (over 6 weeks) with cisplatin versus 60 Gy (over 5 weeks) alone, and RTOG 1016 and DeESCALaTE (Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC), which have randomly assigned patients to 70 Gy plus cisplatin versus cetuximab.21
It should have read as:
In the definitive setting, other efforts include NRG HN002, which has randomly assigned patients to 60 Gy (over 6 weeks) with cisplatin versus 60 Gy (over 5 weeks) alone, and RTOG 1016 and DeESCALaTE (Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC), which have randomly assigned patients to 70 Gy plus cisplatin versus cetuximab.21
This has been corrected as of March 6, 2020. The authors apologize for the error.
